Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease

Exclusion Criteria

• •1. Receiving immunosuppressive treatments such as corticosteroids, hydroxychloroquine, methotrexate, cyclophosphamide, and others within the last 4 weeks.
• •2. Known to have other kidney diseases (e.g., polycystic kidney disease, lupus nephritis, ANCA-associated vasculitis, etc.).
• •3. Known to have other conditions that can cause albuminuria (e.g., myeloma, rhabdomyolysis, paroxysmal nocturnal hemoglobinuria, orthostatic albuminuria, etc.).
• •4. Diagnosed with other types of diabetes (Type 1 DM, gestational DM, or other forms of DM).
• •5. Positive pregnancy test.
• •6. Known to have immunodeficiency diseases such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV); no blood testing required.
• •7. Requires oxygen supplementation.
• •8. Diagnosed with invasive cancer and currently receiving anti-cancer therapy, except for hormonal therapy for breast or prostate cancer.
• •9. History of thromboembolism or a genetic predisposition to thromboembolism, or currently on anti-thromboembolic therapy other than low-dose aspirin.
• •10. Physical or mental disabilities preventing normal daily activities.
• •11. In the investigator's judgment, any illness or medical condition that may hinder the subject's participation, including acute, subacute, intermittent, or chronic diseases that could place the subject at risk of injury, prevent compliance with the study protocol, or interfere with study assessments.
• •12. Measurable parameters include:
• •* Severe obesity: BMI \> 40
• •* Uncontrolled hypertension: systolic \>180 mmHg, diastolic \>100 mmHg
• •13. Unwilling to sign the written informed consent.